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Abstract: The aim in this study was to define the pattern of lymph node metastasis according 
to the primary tumor location. In this retrospective cohort study, each of the operable patients 
diagnosed with lung cancer was grouped by tumor mass location. The International Association 
for the Study of Lung Cancer nodal chart with stations and zones, established in 2009, was used 
to define lymph node levels. From 2006 to 2010, 197 patients underwent a lobectomy with sys-
tematic nodal resection for primary lung cancer at Chiang Mai University Hospital. There were 
123 male and 74 female patients, with ages ranging from 16  –85 years old and an average age of 
61.31. Analyses of tumor location, histology type, and nodal metastasis were performed. The 
locations were the right upper lobe in 63 patients (31.98%), the right middle lobe in 18 patients 
(9.14%), the right lower lobe in 30 patients (15.23%), the left upper lobe in 55 patients (27.92%), 
the left lower lobe in 16 patients (8.12%), and mixed lobes (more than one lobe) in 15 patients 
(7.61%). The mean tumor size was 4.45 cm in diameter (range 1.2–16.5 cm). Adenocarcinoma 
was the most common histological type, which occurred in 132 cases (67.01%), followed by 
squamous cell carcinoma in 41 cases (20.81%), bronchiolo alveolar cell carcinoma in nine 
cases (4.57%), and large cell carcinoma in seven cases (3.55%). Eighteen cases (9.6%) had skip 
metastasis (mediastinal lymph node metastasis without hilar node metastasis). Adenocarcinoma 
and intratumoral lymphatic invasion were the predictors of mediastinal lymph node metastases. 
There were statistically significant differences between a tumor in the right upper lobe and the 
right lower lobe. However, there were no statistically significant differences between tumors in 
the other lobes. In conclusion, tumor location is not a precise predictor of the pattern of nodal 
metastasis. Systematic lymph node dissection is the only way to accurately determine lymph 
node status. Further studies are required for evaluation and conclusions.
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Background and introduction
Lung cancer is a major public health problem worldwide, including in Thailand. The 
most recent data on cancer incidence in Thailand is from the National Cancer Institute 
in Bangkok,1 which indicates lung cancer is the second most common cancer in males 
(24.9%) and the fourth most common cancer in females (9.7%). Currently, there are 
three primary methods of treatment for these patients. Surgical treatment includes 
a complete hilar and mediastinal lymphadenectomy, also called radical systematic 
mediastinal lymph node dissection. With this option, the aim is to achieve better local 
control, an improved survival rate, and complete lung cancer staging. However, the 
prognostic impact (improvement of local control and postoperative survival) of this 
procedure has yet to be determined. Many researchers debate whether systematic nodal 
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dissection or sampling nodal dissection is the most effective 
dissection method. Su et al2 and other researchers3–6 conclude 
that systematic nodal dissection can improve the chances of 
survival and help accurately identify cancer stages. However, 
some researchers7–9 argue that nodal dissection sampling 
is acceptable. Therefore, the present attitude of surgeons 
toward possible mediastinal lymph node metastasis in 
lung cancer varies from one institution to another. Surgical 
options include nodal sampling, radical systematic lymph 
node dissection, and bilateral radical lymph node dissec-
tion via sternotomy because of unanswered questions about 
lymphatic spreading patterns.
This retrospective cohort study was performed to define 
the nodal status of patients diagnosed with lung cancer 
who received surgery to determine the pattern of lymphatic 
drainage in the thorax, which may be useful for surgeons and 
radiologists in estimating nodal involvement and determining 
a surgical strategy.
Patients and methods
After being accepted by the institutional review board, 
197 patients with clinical resectable non-small cell lung 
cancer underwent a lobectomy and systemic nodal resection 
at Chiang Mai University Hospital between January 2006 
and December 2010. The pathological results were retro-
spectively reviewed for 123 male and 74 female patients, 
with ages ranging from 16  –85 years old and an average 
age of 61.31 (Table 1). Before the operation, each patient 
underwent a physical examination, pulmonary function 
test, blood chemistry analysis, plain chest roentgenogra-
phy, and thoracic computed tomography (CT) scanning 
to determine the clinical staging. Based on the CT scans, 
mediastinal lymph nodes less than or equal to 1 cm along 
the short axis were defined as not metastatic. A mediasti-
noscopy with biopsy was performed only in patients with 
mediastinal lymph nodes larger than 1 cm. If mediastinal 
lymph node disease was found, neoadjuvant chemotherapy 
was administered and the patient was excluded from this 
study. Positron emission tomography is not available at 
our institute. Patients diagnosed with pathological nodal 
group 2 disease and treated with neoadjuvant chemotherapy 
were also excluded from this study. Eleven patients in this 
study received an open thoracotomy, lobectomy, and rou-
tine systematic nodal dissection, in accordance with The 
International Association for the Study of Lung Cancer,10 
regardless of tumor size or histology type. All dissected 
lymph nodes were sent for pathological examination and 
metastatic status determination. Those with pathological 
nodal group 2 disease received postoperative chemotherapy. 
If the tumor invaded more than one lobe, a bilobectomy was 
performed. The collected data included age, sex, primary 
tumor location and size, histological types, nodal sites, and 
pathological staging. Each nodal site was divided into four 
categories. The upper mediastinal nodal group included 
low cervical nodes (station 1), upper paratracheal nodes 
(station 2), prevascular and retrotracheal nodes (station 3), 
and lower paratracheal nodes (station 4). The lower medi-
astinal nodal group included subcarinal nodes (station 7), 
paraesophageal nodes (station 8), and pulmonary ligament 
nodes (station 9). The intrapulmonary nodal group included 
hilar nodes (station 10), interlobar nodes (station 11), 
lobar nodes (station 12), segmental nodes (station 13), 
and subsegmental nodes (station 14). The aortopulmonary 
Table 1 Patient characteristics
Characteristics Number (%)
gender
  Male 123 (62.5)
  Female 74 (37.6)
Age (year) mean ± SD 61.3 ± 11.0
histology type
  Adenocarcinoma 132 (67.0)
  Squamous cell carcinoma 41 (20.9)
  Others 24 (12.2)
Tumor location
  Right upper lobe 63 (32.0)
  Right middle lobe 18 (9.1)
  Right lower lobe 30 (15.2)
  Left upper lobe 55 (28.0)
  Left lower lobe 16 (8.1)
  Right upper lobe adhered to right middle lobe 11 (5.6)
  Right lower lobe adhered to right middle lobe 2 (1.0)
  Left upper lobe adhered to left lower lobe 2 (1.0)
Pathological tumor status
  T1a 14 (7.1)
  T1b 46 (23.4)
  T2a 93 (47.2)
  T2b 23 (11.7)
  T3 21 (10.7)
  T4 0 (0)
Pathological nodal status
  N0 128 (65.0)
  N1 19 (9.6)
  N2 50 (25.4)
  N3 0 (0)
Pathological staging
  ia 38 (19.3)
  ib 59 (30.0)
  iia 30 (15.2)
  iib 17 (8.6)
  iiia 53 (26.9)
  iiib 0 (0)
  iV 0 (0)
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nodal group included subaortic (aortopulmonary window) 
nodes (station 5) and para-aortic nodes (ascending aorta or 
phrenic) (station 6).
Statistical analysis was performed using the STATA 
statistical package. The data was expressed as mean and 
standard deviation unless otherwise stated. A student’s 
t-test was used to ascertain the statistical significance of two 
continuous variables. Fisher exact probability analysis was 
performed to test for differences in proportions of categorical 
variables between two or more groups. The diagnostic 
accuracy parameters were compared using compatible 
statistical analysis. Univariable and multivariable logistic 
regression analyses were used to control the confounders. The 
level of significance was set to a P value of less than 0.05.
Results
Patient characteristics
There were 197 patients whose primary lung cancer was 
clinically classified as resectable disease (stage IA, IB, IIA, 
IIB, and some instances of IIIA). The age range of the patients 
was from 16–85 years, with a mean age of 61.3. Preoperative 
mediastinoscopic biopsies were performed for 27 patients 
(13.7%) and these patients were negative for malignant cells. 
Twenty-one patients were excluded from this study because 
of a positive mediastinal lymph node based on a mediastino-
scopic biopsy (not included in the 197 patients). Lymph node 
station one or low cervical node (N3 group) was dissected 
in two patients and was negative for malignant cells (no 
metastasis). Primary tumors were located in the right upper 
lobe (RUL) in 63 cases (32.0%), in the right middle lobe 
(RML) in 18 cases (9.1%), in the right lower lobe (RLL) in 
30 cases (15.2%), in the left upper lobe (LUL) in 55 cases 
(28.0%), in the left lower lobe (LLL) in 16 cases (8.1%), 
in both RULs adhered to the RML in 11 cases (5.6%), in 
the RLL adhered to the RML in two cases (1.0%), and in 
the LUL adhered to the LLL in two cases (1.0%). Tumors 
were typed and staged as shown in Tables 1 and 2. Two cases 
were pathologically diagnosed as small cell carcinoma since 
the preoperative diagnoses were unavailable.
The predictors of intrathoracic lymph 
node metastases
These patients were divided into two groups, negative malig-
nant cells in the intrathoracic lymph node group and positive 
Table 2 histological cell type in each lobe
Adenocarcinoma BAC SCCA Small cell CA Large cell CA Neuro-endocrine Total (%)
RUL 47 2 10 – 2 1 63 (32.0)
RML 11 2 3 2 18 (9.1)
RLL 20 1 6 1 2 – 30 (15.2)
LUL 31 1 21 1 1 1 55 (29.9)
LLL 14 2 1 16 (8.1)
Mixed 9 2 2 2 15 (7.6)
Abbreviations:  BAC,  Bronchioloalveolar  carcinoma;  SCCA,  squamous  cell  carcinoma;  RUL,  right  upper  lobe;  RML,  right  middle  lobe;  RLL,  right  lower  lobe;   
LUL, left upper lobe; LLL, left lower lobe; Mixed, RUL and RML or RLL and RML.
Table 3 Patient characteristics of positive and negative malignant cells in intrathoracic lymph nodes
Characteristics Negative malignant cells  
in intrathoracic LN  
N = 128
Positive malignant cells  
in intrathoracic LN  
N = 69
P value
Tumor size, cm (mean ± SD) 4.7 ± 2.5 4.3 ± 2.3 0.852
Histology type (number (%))
Small cell carcinoma 2 (1.6) 0 (0.0) 0.543
Non-small cell carcinoma 126 (98.4) 69 (100.0) 0.043
  Adenocarcinoma 107 (83.6) 66 (95.7) 0.012
  Squamous cell carcinoma 9 (7.0) 0 (0.0) 0.028
  Others 10 (7.8) 3 (4.4) 0.549
Lymphatic invasion 100 (78.1) 64 (92.6) 0.009
Cell differentiated 0.123
Well differentiated 13 (10.2) 2 (2.9) 0.091
Moderately differentiated 36 (28.1) 28 (40.6) 0.082
Poorly differentiated 50 (39.1) 27 (39.1) 1.000
Undifferentiated 29 (22.7) 12 (17.4) 0.463
Note: intrathoracic lymph nodes refer to mediastinal lymph nodes (N2 group) and intrapulmonary lymph node (N1 group).
Abbreviation: LN, lymph node.
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malignant cells in the intrathoracic lymph node group. Patient 
characteristics, including tumor size, histology types, intratu-
moral lymphatic invasion, and cell differentiation are shown 
in Table 3. There were statistically significant differences in 
histology types and lymphatic invasion. Patients diagnosed 
with adenocarcinoma or intratumoral lymphatic invasion 
showed more significant risk of metastases to intrathoracic 
lymph nodes than those with other cell types or were negative 
for lymphatic invasion.
Univariable and multivariable analyses showed that 
adenocarcinoma and lymphatic invasion were predic-
tors of intrathoracic lymph node metastases, as shown in 
Tables 4 and 5.
Postoperative complications
Of the 197 patients, a lobectomy was performed in 188 cases 
(95.4%) and a bilobectomy was performed in nine cases 
(4.6%). Eight patients received an RLL and RML lobectomy 
and one case required an RUL and RML lobectomy.
Three patients (1.5%) died after surgery. These patients 
developed respiratory failure, hospital-acquired pneumonia, 
septicemia, and multiple organ failure. They had chronic 
obstructive pulmonary disease, hypertension, and diabetes 
mellitus.
Postoperative complications included air leakage in 
19 cases (9.7%) (two cases needed a second operation to repair 
lung parenchyma), respiratory failure in three cases (1.5%) (all 
cases had their endotracheal tube removed within one week 
after surgery), chylothorax in two cases (1.0%) (one of which 
needed rethoracotomy for a mass ligation of the thoracic 
duct), hemothorax in two cases (1.0%) (one case had bleed-
ing from an intercostal artery and another case had bleeding 
from a raw surface after trying to dissect the tumor from the 
parietal pleura; both cases required reoperation to stop the 
bleeding), and atelectasis in three cases (1.5%) (caused by 
secretion obstruction and treated with a bronchoscopy with 
suction). The summary of postoperative complications and 
lengths of hospital stays are shown in Table 6.
Distribution of nodes in each location
The distribution of pathological nodal status according to 
the location of primary tumors is shown in Table 7. The rate 
of lower mediastinal node metastases in patients who had 
tumors located in their RLL was significantly higher than 
that of patients who had tumors located in their RUL (odds 
ratio = 10.4, P value = 0.007, calculated by multivariable 
logistic regression analysis, shown in Tables 8 and 12). The 
rate of lower mediastinal node metastases in patients who had 
a tumor located in the LLL was significantly higher than that 
of patients who had a tumor located in the LUL (Table 9). 
However, there was no statistically significant difference 
when calculated using multivariable logistic regression 
analysis, as shown in Table 12.
Table 13 shows the relationship between the loca-
tion of the primary tumor and the prevalence of skip 
mediastinal lymph node metastases. Skip metastases was 
defined as metastatic foci in the mediastinal lymph node 
group, whereas the hilar mediastinal nodes were   negative. 
Approximately 9.1% of patients (18 patients) in this 
study had skip metastases. There were eleven (10.3%) of 
107 patients with primary tumors of the upper lobe who 
exhibited skip metastases versus four (8.7%) of 46 patients 
with primary tumors of the lower lobe (not significant, 
P value = 0.738).
Table 14 shows the relationship between the primary 
tumor site with positive intrathoracic lymph node metas-
tases and the level of mediastinal lymph node metastases. 
Table 4 Univariable logistic regression analysis of factors that 
influence positive malignant cells in intrathoracic lymph nodes
Factors Odds ratio 95% CI P value
Size 1.0 0.9–1.1 0.851
Adenocarcinoma* 4.3 1.2–5.0 0.022
Lymphatic invasion** 3.6 1.3–9.8 0.013
Severe and undifferentiated*** 0.8 0.4–1.5 0.478
Notes:  *Compared  with  other  cell  types;  **compared  with  negative  lymphatic 
invasion; ***compared with well and moderately differentiated.
Abbreviation: CI, confidence interval.
Table 5 Multivariable logistic regression analysis of factors that 
influence the positive malignant cells in intrathoracic lymph nodes
Factors Odds ratio 95% CI P value
Size 1.0 0.9–1.2 0.614
Adenocarcinoma* 4.3 1.1–16.3 0.034
Lymphatic invasion** 3.2 1.1–9.1 0.031
Severe and undifferentiated*** 0.5 0.3–1.0 0.060
Notes:  *Compared  with  other  cell  types;  **compared  with  negative  lymphatic 
invasion; ***compared with well and moderately differentiated.
Abbreviation: CI, confidence interval.
Table 6 Postoperative status and complications
Postoperative status Number of patients (%)
No complication 165 (83.7)
Air leak 19 (9.7)
Respiratory failure 3 (1.5)
Chylothorax 2 (1.0)
hemothorax 2 (1.0)
Atelectasis 3 (1.5)
Death 3 (1.5)
hospital stay, days (mean ± SD) 8.8 ± 5.1
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Table 7 Distribution of nodes in each location
LN station RUL (N = 21)  
N (%)
RML (N = 6)  
N (%)
RLL (N = 13)  
N (%)
LUL (N = 21)  
N (%)
LLL (N = 4)   
N (%)
Positive  
Upper mediastinal node  
(station 1–4)
 
12 (57.1)
 
2 (33.3)
 
5 (38.5)
 
7 (33.3)
 
2 (50.0)
Lower mediastinal node  
(station 7–9)
2 (9.52) 3 (50.0) 9 (69.2) 7 (33.3) 4 (100.0)
intrapulmonary node  
(station 10–14)
21 (100.0) 5 (83.3) 13 (100.0) 21 (100.0) 4 (100.0)
AP window node  
(station 5–6)
– – – 12 (57.1) 2 (50.0)
Abbreviations: RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe; LN, lymph node.
Table 8 Distribution of metastatic lymph nodes compared with 
site of tumor between RUL and RLL
Intrathoracic LN group RUL  
N (%)
RLL  
N (%)
P value
Upper mediastinal node  
(station 1–4)
12 (57.1) 5 (38.5) 0.481
Lower mediastinal node  
(station 7–9)
2 (9.5) 9 (69.2) 0.001
intrapulmonary node  
(station 10–14)
21 (100.0) 13 (100.0) –
Abbreviations:  RUL,  right  upper  lobe;  RML,  right  middle  lobe;  RLL,  right   
lower lobe.
Table 9 Distribution of metastatic lymph nodes compared with 
site of tumor between LUL and LLL
Intrathoracic LN group LUL  
N (%)
LLL  
N (%)
P value
Upper mediastinal node 
(station 1–4)
7 (33.3) 2 (50.0) 0.602
Lower mediastinal node 
(station 7–9)
7 (33.3) 4 (100.0) 0.026
Aortopulmonary window node  
(station 5, 6)
12 (57.1) 2 (50.0) 1.000
intrapulmonary node  
(station 10–14)
21 (100.0) 4 (100.0) –
Abbreviations: LN, lymph node; LUL, left upper lobe; LLL, left lower lobe.
rate of morbidity and mortality, operative time, and blood 
loss and has the least efficacy. If the lymphatic drainage 
route and incidence of lymph node metastasis correlated 
to the anatomical location of the lobe that involved the 
primary tumor, the optimal extent of lymph node dissec-
tion should be based on the incidence of metastasis to each 
mediastinal station.
Systematic nodal dissection in lung cancer is our routine 
procedure despite clinical stage I non-small cell lung cancer 
(NSCLC) because of the relatively high false negative rate 
of CT scanning.12–14 We categorize the mediastinal lymph 
nodes according to the classification by the International 
Association for the Study of Lung Cancer, which has been 
universally accepted since its introduction (first introduced 
by Naruke et al20). There were few complications of medi-
astinal lymph node dissection, such as chylothorax, in this 
series (only 1%) and overall complications were 16.3%, 
mainly due to postoperative air leakage. The 30-day mortal-
ity rate was 1.3%.
Our data demonstrated adenocarcinoma and intratumoral 
lymphatic invasions are influencing factors for the incidence 
and extent of metastasis of intrathoracic lymph nodes in 
  Sixty-eight (34.5%) patients had pathologically proven 
mediastinal lymph node metastases despite being clinically 
negative for   mediastinal lymph node metastases and 52.9% 
of patients who were clinically negative for mediastinal 
lymph node metastases showed multiple-level mediastinal 
metastases. There was no statistically significant difference 
between the sites of primary tumors that had intra-thoracic 
lymph node metastases and the level of mediastinal lymph 
node metastases (P value = 0.223 based on a Fisher exact 
probability test).
Discussion
Lymph node dissection of the pulmonary hilum and medi-
astinum combined with a lobectomy was first introduced 
by Cahan11 as an alternative to the pneumonectomy, which 
was respected as a standard mode of surgery. Cahan first 
postulated that the extent of dissection should be based on 
the lobe where the primary tumor was located and stated that 
a bilobectomy should be performed for tumors of the RML 
or RLL. However, his proposal regarding the extent of dis-
section was not based on a detailed analysis of the incidence 
of involvement in each mediastinal location.
The dissection of a mediastinal lymph node in each 
station with the least possibility of metastasis increases the 
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Table 13 Location of primary tumor and skip nodal metastases
Primary  
tumor site
No skip metastases  
N (%)
Skip metastases   
N (%)
RUL (n = 63) 58 (92.1) 5 (7.9)
RML (n = 18) 15 (83.3) 3 (16.7)
RLL (n = 30) 26 ( 86.7) 4 (13.3)
LUL (n = 55) 49 ( 89.1) 6 (10.9)
LLL (n = 16) 16 (100.0) 0 (0.0)
Note: Skip metastases were defined as metastatic foci in the mediastinal lymph 
node (N2) group without metastasis to the hilar mediastinal node.
Abbreviations: RUL, right upper lobe; RML, right middle lobe; RLL, right lower 
lobe; LUL, left upper lobe; LLL, left lower lobe.
Table  12  Multivariable  logistic  regression  analysis  of  intra-
thoracic lymph node metastases compared among upper, lower, 
and middle lobes (confounders include size of tumor, histology 
type, cell differentiated, and lymphatic invasion)
Intrathoracic lymph nodes Odds ratio 95% CI P value
RLL vs RUL 
Upper mediastinal node  
(station 1–4)
 
0.7
 
0.2–2.4
 
0.543
Lower mediastinal node  
(station 7–9)
10.4 1.9–58.0 0.007
intrapulmonary node  
(station 10–14)
1.2 0.4–3.6 0.687
RLL vs RML 
Upper mediastinal node  
(station 1–4)
 
3.0
 
0.4–23.7
 
0.301
Lower mediastinal node  
(station 7–9)
1.8 0.3–1.5 0.515
intrapulmonary node  
(station 10–14)
2.6 0.5–15.1 0.284
RUL vs RML 
Upper mediastinal node  
(station 1–4)
 
0.6
 
0.1–3.1
 
0.550
Lower mediastinal node  
(station 7–9)
6.4 0.9–44.5 0.061
intrapulmonary node  
(station 10–14)
0.7 0.2–3.0 0.642
LLL vs LUL 
Upper mediastinal node  
(station 1–4)
 
0.7
 
0.1–4.4
 
0.748
Lower mediastinal node  
(station 7–9)
1.6 0.4–7.0 0.534
Aortopulmonary window node  
(station 5, 6)
0.4 0.1–2.3 0.312
Abbreviations:  CI,  confidence  interval;  RUL,  right  upper  lobe;  RML,  right   
middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe.
Table 11 Distribution of metastatic lymph nodes compared with 
site of tumor between RLL and RML
Intrathoracic LN group RLL  
N (%)
RML  
N (%)
P value
Upper mediastinal node 
(station 1–4)
5 (38.5) 4 (66.7) 1.000
Lower mediastinal node 
(station 7–9)
9 (69.2) 3 (50.0) 0.617
intrapulmonary node 
(station 10–14)
13 (100.0) 5 (83.3) 0.316
Abbreviations: LN, lymph node; RML, right middle lobe; RLL, right lower lobe.
Table 10 Distribution of metastatic lymph nodes compared with 
site of tumor between RUL and RML
Intrathoracic LN group RUL  
N (%)
RML  
N (%)
P value
Upper mediastinal node 
(station 1–4)
12 (57.1) 2 (33.3) 0.385
Lower mediastinal node 
(station 7–9)
2 (9.5) 3 (50.0) 0.056
intrapulmonary node 
(station 10–14)
21(100.0) 5 (83.3) 0.222
Abbreviations: RUL, right upper lobe; RML, right middle lobe; LN, lymph node.
operable NSCLC patients. Those who had adenocarcinoma 
or intratumoral lymphatic invasion showed a significantly 
higher incidence of mediastinal lymph node metastases. 
However, the incidence of mediastinal lymph node metas-
tases did not correlate significantly with tumor sizes, as 
reported in a previous study.15
The preoperative evaluation of the intrathoracic nodal sta-
tus based on a CT scan remains a feature since normal sized 
nodes could be cancer positive upon pathological examina-
tion, as shown in Table 3. Approximately 61.7% of patients 
were preoperatively understaged based on the CT scan. At 
our institution, 69 (35%) of 197 patients preoperatively 
diagnosed with no mediastinal lymph node metastasis by CT 
scan were revealed to be N1-2 upon pathological examina-
tion after surgery. Preoperative evaluation of nodal status by 
CT scan is thus not enough to decide the appropriateness of 
limited resection for NSCLC.16,17 Although positron emis-
sion tomography with a CT scan has been used worldwide 
in recent years, it remains unavailable in many countries, 
including Thailand.
Our data shows that more than half (52.9%) of clinical 
node negative patients showed multiple-level mediastinal 
metastases. The results of this study are similar to those 
of Keller and associates (Eastern Cooperative Oncology 
Group),18 who reported that complete mediastinal lymph 
node dissection had identified significantly more levels of 
mediastinal involvement, but in patients with small sized 
NSCLC.
Okada et al19 and Naruke et al20 show that tumors in 
the RUL developed extensive multiple-level mediastinal 
involvement within the upper, middle, and lower mediasti-
nal lymph nodes, whereas tumors originating in the LUL 
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metastasized within the upper, lower, and aortopulmonary 
window mediastinal lymph nodes. These results comple-
ment our findings. Only tumors located in the RUL have 
more risk for metastases to the upper mediastinal lymph 
nodes than those in the RLL. However, tumors from other 
sites have no statistically significant difference in the level 
of mediastinal lymph node metastases. Therefore, the pat-
tern of mediastinal lymph node metastasis is not compat-
ible with the primary site of the tumor. However, 40% of 
lower lobe (RLL and LLL) with mediastinal lymph node 
metastases had nodal metastasis to the upper mediastinal 
lymph node and 20% of upper lobe (RUL and LUL) with 
mediastinal lymph node metastases had nodal metastasis 
to the lower mediastinal lymph node. This incidence was 
lower than that in previous reports.15,21 In the aortopulmo-
nary window node, the LUL lesion tends to metastasize 
more than in the LLL lesion, but this finding is not statisti-
cally significant.
Takizawa et al22 and Oda et al15 show that the location of 
the primary tumor corresponds to the mediastinal area where 
lymph nodes are likely to be diseased and that the frequency 
of nodal metastasis of a single level is high. This was also 
seen in our series, as shown in Tables 13 and 14. There are 
9.6% more cases of skip metastasis than were found in a 
previous study.23
Conclusion
There is no definite way to identify lymphatic spreading. 
It seems that upper lobe lesions not only metastasize to an 
upper mediastinal node level, but also metastasize to a lower 
mediastinal node level. On the contrary, lower lobe lesions 
not only metastasize to a lower mediastinal node level, but 
also involve the upper mediastinal node level. Tumor loca-
tion alone is no longer a predictive factor for the pattern of 
nodal involvement; therefore, systematic lymph node dissec-
tion remains the only way for us to determine lymph node 
status. However, further studies are required for evaluation 
and conclusions regarding this view.
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